Abstract
Background: In children with cancer and high risk febrile neutropenia (HRFN), the initial empirical treatment used in our hospital for 5 years includes the association of Cloxacillin + Ceftazidime + Amikacin. There is no chilean literature that reviews the effectiveness of this therapy.
Objective: Evalúate the clinical and microbiological effectiveness of this associated therapy in children with HRFN.
Method: A prospective-descriptive study evaluating children with HRFN admitted at Hospital Luis Calvo Mackenna between January 2005-August 2006.
Results: 100 HRFN episodes were evaluated. In 48% of cases, the antimicrobial treatment was considered effective, whereas in 52% of episodes the therapy required modifications (15% cases within the first 72 hours). The most frequent diagnoses were fever without clinical focus (51%) and sepsis (13%). 36% had microbiological identification and the most frequently isolated bacteria were Escherichia coli (9%) and Staphylococcus aureus (9%).
Conclusions: A favorable answer with the initial empirical therapy was obtained for 48% of cases; meanwhile in the remaining episodes, 28% required antibiotics modifications without justification. This fact remarks the importance of following the established guidelines for antimicrobial treatment modification in these patients.
Los contenidos publicados en esta revista están protegidos bajo una Licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esto significa que cualquier persona es libre de compartir, usar y construir a partir de este artículo, incluso con fines comerciales, siempre que se otorgue el crédito apropiado al autor original, se proporcione un enlace a la licencia, se indique el nombre y edición de la Revista.
Esta licencia no impone restricciones adicionales, lo que garantiza la libre circulación y reutilización del conocimiento con respeto y transparencia hacia los derechos de los autores. (Véase El efecto del acceso abierto).